Other: Intensify treatment with the existing drug ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 96 | Crohn disease | 1 |
| 97 | Ulcerative colitis | 1 |
96. Crohn disease
Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01960426 (ClinicalTrials.gov) | April 2014 | 25/9/2013 | Evaluation of Health Costs and Resource Utilization | A Randomized Evaluation of Health Costs and Resource Utilization Comparing Testing-Based Therapy to Empiric Dose Intensification for the Management of Inflammatory Bowel Disease. | Ulcerative Colitis;Crohn's Disease | Other: Measurement of drug (Adalimumab/Infliximab);Other: Intensify treatment with the existing drug | University of Western Ontario, Canada | Prometheus Laboratories | Terminated | 18 Years | N/A | Both | 51 | Phase 4 | United States |
97. Ulcerative colitis
Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01960426 (ClinicalTrials.gov) | April 2014 | 25/9/2013 | Evaluation of Health Costs and Resource Utilization | A Randomized Evaluation of Health Costs and Resource Utilization Comparing Testing-Based Therapy to Empiric Dose Intensification for the Management of Inflammatory Bowel Disease. | Ulcerative Colitis;Crohn's Disease | Other: Measurement of drug (Adalimumab/Infliximab);Other: Intensify treatment with the existing drug | University of Western Ontario, Canada | Prometheus Laboratories | Terminated | 18 Years | N/A | Both | 51 | Phase 4 | United States |